242 related articles for article (PubMed ID: 1663726)
1. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD
Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726
[TBL] [Abstract][Full Text] [Related]
2. 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections.
Gangemi JD; Cozens RM; De Clercq E; Balzarini J; Hochkeppel HK
Antimicrob Agents Chemother; 1989 Nov; 33(11):1864-8. PubMed ID: 2482011
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.
Neyts J; Sobis H; Snoeck R; Vandeputte M; De Clercq E
Eur J Clin Microbiol Infect Dis; 1993 Apr; 12(4):269-79. PubMed ID: 8390357
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
5. Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine.
Smee DF; Morris JL; Leonhardt JA; Mead JR; Holy A; Sidwell RW
Antimicrob Agents Chemother; 1992 Sep; 36(9):1837-42. PubMed ID: 1329629
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
De Clercq E; Holý A
Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
[TBL] [Abstract][Full Text] [Related]
7. Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice.
Yang H; Datema R
Antimicrob Agents Chemother; 1991 Aug; 35(8):1596-600. PubMed ID: 1929331
[TBL] [Abstract][Full Text] [Related]
8. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
9. Effects of phosphonylmethoxyalkyl-purine and -pyrimidine derivatives on TK+ and TK- HSV-1 keratitis in rabbits.
Maudgal PC; De Clercq E
Antiviral Res; 1991 Jul; 16(1):93-100. PubMed ID: 1663731
[TBL] [Abstract][Full Text] [Related]
10. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.
Neyts J; Balzarini J; Naesens L; De Clercq E
J Med Virol; 1992 May; 37(1):67-71. PubMed ID: 1320099
[TBL] [Abstract][Full Text] [Related]
12. Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.
Stals FS; Zeytinoglu A; Havenith M; de Clercq E; Bruggeman CA
Antimicrob Agents Chemother; 1993 Feb; 37(2):218-23. PubMed ID: 8383939
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC.
Kloover JS; Vanagt WY; Stals FS; Bruggeman CA
Antiviral Res; 1997 Jul; 35(2):105-12. PubMed ID: 9217247
[TBL] [Abstract][Full Text] [Related]
14. Acute murine cytomegalovirus infection: a model for determining antiviral activity against CMV induced hepatitis.
Bolger G; Lapeyre N; Rhéaume M; Kibler P; Bousquet C; Garneau M; Cordingley M
Antiviral Res; 1999 Dec; 44(3):155-65. PubMed ID: 10651067
[TBL] [Abstract][Full Text] [Related]
15. Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine.
Flores-Aguilar M; Huang JS; Wiley CA; De Clercq E; Vuong C; Bergeron-Lynn G; Chandler B; Munguia D; Freeman WR
J Infect Dis; 1994 Mar; 169(3):642-7. PubMed ID: 8158041
[TBL] [Abstract][Full Text] [Related]
16. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
Stals FS; de Clercq E; Bruggeman CA
Antimicrob Agents Chemother; 1991 Nov; 35(11):2262-6. PubMed ID: 1666493
[TBL] [Abstract][Full Text] [Related]
17. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.
Lalezari JP; Drew WL; Glutzer E; Miner D; Safrin S; Owen WF; Davidson JM; Fisher PE; Jaffe HS
J Infect Dis; 1994 Sep; 170(3):570-2. PubMed ID: 8077713
[TBL] [Abstract][Full Text] [Related]
18. Effects of monoclonal antibody combined with ganciclovir or (S)-1-[3-hydroxy-(2-phosphonylmethoxy)-propyl]cytosine against murine cytomegalovirus infections in cell culture and in severe combined immunodeficient mice.
Smee DF; Sugiyama ST; Sidwell RW; Barnett BB
Chemotherapy; 1995; 41(2):141-8. PubMed ID: 7758358
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus.
Smee DF; Barnett BB; Sidwell RW; Reist EJ; Holy A
Antiviral Res; 1995 Jan; 26(1):1-9. PubMed ID: 7741517
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
